The medical community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s exhibiting significant potential in clinical trials for managing obesity. Unlike some current weight loss solutions, retatrutide appears to offer a more substantial reduction in body size and enhance metabolic health, particularly conc